Stocks Health care HOWL
NASDAQ · Health careWerewolf Therapeutics, Inc. (HOWL)
It posted a net loss of $34.6M. In fiscal 2025 capital spending exceeded operating cash flow by $60.3M. At June 30, 2026 it held $22M in cash. Its latest periodic report to the SEC is the quarterly report (10-Q) filed on July 31, 2026.
Key facts about Werewolf Therapeutics, Inc.
- Net worth
- Werewolf Therapeutics, Inc. has a market value (market cap) of $47.1M at the latest share price, and shareholders' equity of $16.3M on its balance sheet at June 30, 2026. A company's "net worth" usually means one of these: what the market pays for all its shares, or its assets minus its liabilities.
- Cash flow
- In fiscal 2025 operations used $60.3M of cash.
- Latest report
- The latest periodic report (quarterly report, 10-Q) was filed with the SEC on July 31, 2026 and covers the period to June 30, 2026. Open on SEC EDGAR
- Next earnings report
- Werewolf Therapeutics, Inc.'s next report was expected around November 3, 2026 and is not on file with the SEC yet.
What Werewolf Therapeutics, Inc. does
Werewolf Therapeutics, Inc. is registered with the SEC under industry code SIC 2834 (Pharmaceutical Preparations). Its shares trade on NASDAQ under the ticker HOWL.
Revenue and profit by year
Key figures
| Fiscal year | Revenue | Net income | Diluted EPS | Free cash flow |
|---|---|---|---|---|
| 2025 | n/a | -$60.8M | -$1.33 | -$60.3M |
| 2024 | n/a | -$70.5M | -$1.63 | -$56.4M |
| 2023 | n/a | -$37.4M | -$1.05 | -$33.4M |
| 2022 | n/a | -$53.8M | -$1.86 | -$44.2M |
| 2021 | n/a | -$50M | -$10.94 | -$43.4M |
| 2021 | n/a | -$15M | -$28.08 | -$19.2M |
Earnings: every quarter and the next report date
Full financial statements: income, balance sheet and cash flow
Latest SEC filings
What Werewolf Therapeutics, Inc. has filed recently, newest first. Each links to the original document on SEC EDGAR.
- September 22, 2026
- September 21, 2026Passive stake (5% or more) SCHEDULE 13G
- August 21, 2026Form 425 filing 425
- August 21, 2026
- August 20, 2026
- July 31, 2026
- July 31, 2026
- July 2, 2026Activist stake changed SCHEDULE 13D/A
- June 26, 2026Activist stake changed SCHEDULE 13D/A
- June 22, 2026Activist stake changed SCHEDULE 13D/A
Insider trades
What the people running Werewolf Therapeutics, Inc. did with its shares, from the Form 4 filings they must send the SEC within two business days.
No insider trades were reported in the last 90 days.
| Date | Insider | What | Shares | Value |
|---|---|---|---|---|
| July 7, 2026 | Evnin LukeDirector | Soldpre-planned (10b5-1), indirect | 107,429 | $33.3K |
| July 6, 2026 | Evnin LukeDirector | Soldpre-planned (10b5-1), indirect | 35,770 | $11.4K |
| June 29, 2026 | Evnin LukeDirector | Soldpre-planned (10b5-1), indirect | 157,084 | $47.1K |
| June 17, 2026 | Ra Capital Management, L.P.10% owner | Soldindirect | 389,216 | $136.2K |
| June 17, 2026 | Ra Capital Management, L.P.10% owner | Soldindirect | 27,695 | $9.7K |
| June 16, 2026 | Ra Capital Management, L.P.10% owner | Soldindirect | 139,686 | $51.7K |
| June 16, 2026 | Ra Capital Management, L.P.10% owner | Soldindirect | 9,939 | $3.7K |
| June 15, 2026 | Ra Capital Management, L.P.10% owner | Soldindirect | 120,216 | $46.9K |
Who owns HOWL
Three views from three kinds of SEC filings, each with its own date. They overlap and are not added up.
5% holders
| Holder | Of class | Filed |
|---|---|---|
| Moll Peter13G, passive | 5.2% | September 21, 2026 |
Largest institutional holders
Insiders
3 insiders reported holding 9,871,941 shares in total, about $9.6M at the last price.
| Holder | Shares |
|---|---|
| Gadicke AnsbertFormer 10% Owner | 4,784,1114,784,111 held indirectly |
| MPM BioVentures 2014, L.P.Former 10% Owner | 4,784,1114,784,111 held indirectly |
| Ra Capital Management, L.P.10% owner | 303,719303,719 held indirectly |
Questions about HOWL
What does Werewolf Therapeutics, Inc. do?
Werewolf Therapeutics, Inc. is a company in the Health care sector, listed on NASDAQ as HOWL. Its shares trade on NASDAQ under the ticker HOWL.
What is Werewolf Therapeutics, Inc.'s net worth?
Werewolf Therapeutics, Inc. has a market value (market cap) of $47.1M at the latest share price, and shareholders' equity of $16.3M on its balance sheet at June 30, 2026. A company's "net worth" usually means one of these: what the market pays for all its shares, or its assets minus its liabilities.
Is Werewolf Therapeutics, Inc. profitable?
No. Over the twelve months to June 30, 2026 it reported a net loss of $34.6M.
When did Werewolf Therapeutics, Inc. last report?
Its most recent periodic report is the quarterly report (10-Q) filed on July 31, 2026. It covers the period to June 30, 2026. Its newest filing of any kind is the merger registration from September 22, 2026.
When is Werewolf Therapeutics, Inc.'s next earnings report?
Werewolf Therapeutics, Inc.'s next report was expected around November 3, 2026 and is not on file with the SEC yet.
Similar companies
Compare HOWL with
Follow HOWL
Get an email when Werewolf Therapeutics, Inc. files with the SEC: results, executive changes, material agreements and annual reports.
Where the numbers come from
Financial figures are the values Werewolf Therapeutics, Inc. tagged in its own SEC filings (XBRL), taken from the latest filing for each period, so restatements replace older figures. Revenue, profit and cash flow are for full fiscal years unless marked as the last twelve months, which is the sum of the four most recent quarters. Where a company reports only the full year, the fourth quarter is the year minus the first three.
Prices are delayed end-of-day market data in the listing currency, and market cap moves with the price. P/E is shown only when earnings per share are positive. Nothing here is investment advice.